Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ECORNASDAQ:IRIXNASDAQ:NDRANASDAQ:SLNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeECORelectroCore$6.03+12.5%$5.55$4.47▼$19.49$44.74M0.8100,190 shs185,164 shsIRIXIRIDEX$0.92+0.6%$1.02$0.78▼$2.41$15.38M0.5752,112 shs5,488 shsNDRAENDRA Life Sciences$3.46-4.0%$3.84$2.90▼$170.63$2.56M-0.18141,516 shs10,716 shsSLNOSoleno Therapeutics$86.64+0.5%$77.64$40.19▼$87.16$4.37B-2.63789,814 shs330,112 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceECORelectroCore+12.50%+11.67%+16.41%+6.54%-5.78%IRIXIRIDEX+0.64%+3.37%-4.58%+6.28%-55.75%NDRAENDRA Life Sciences-4.03%-1.57%-0.72%-0.58%-99.96%SLNOSoleno Therapeutics+0.49%+3.11%+11.95%+28.39%+106.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationECORelectroCore2.3544 of 5 stars3.53.00.00.00.02.50.6IRIXIRIDEX0.5546 of 5 stars0.04.00.00.00.91.70.0NDRAENDRA Life Sciences3.1974 of 5 stars3.55.00.00.02.20.01.3SLNOSoleno Therapeutics4.211 of 5 stars3.52.00.04.61.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceECORelectroCore 3.00Buy$25.50322.89% UpsideIRIXIRIDEX 0.00N/AN/AN/ANDRAENDRA Life Sciences 3.00Buy$50.001,347.18% UpsideSLNOSoleno Therapeutics 3.09Buy$107.1023.62% UpsideCurrent Analyst Ratings BreakdownLatest NDRA, SLNO, ECOR, and IRIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025SLNOSoleno TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/23/2025SLNOSoleno TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$110.005/8/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$81.00 ➝ $97.005/8/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$102.00 ➝ $105.004/24/2025SLNOSoleno TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$93.00 ➝ $145.004/21/2025NDRAENDRA Life SciencesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $50.004/15/2025SLNOSoleno TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookECORelectroCore$25.18M1.78N/AN/A$1.13 per share5.34IRIXIRIDEX$48.67M0.32N/AN/A$0.13 per share7.05NDRAENDRA Life SciencesN/AN/AN/AN/A$4.77 per shareN/ASLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateECORelectroCore-$11.89M-$1.56N/AN/AN/A-46.24%-149.04%-61.24%8/6/2025 (Estimated)IRIXIRIDEX-$8.91M-$0.43N/A∞N/A-14.61%-290.57%-22.86%8/6/2025 (Estimated)NDRAENDRA Life Sciences-$11.51M-$172.04N/AN/AN/AN/A-140.96%-106.14%8/13/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.62N/AN/AN/AN/A-77.52%-63.44%8/6/2025 (Estimated)Latest NDRA, SLNO, ECOR, and IRIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IRIXIRIDEX-$0.10-$0.10N/A-$0.10$12.10 million$11.90 million5/7/2025Q1 2025ECORelectroCore-$0.56-$0.47+$0.09-$0.47$6.93 million$6.72 million5/7/2025Q1 2025SLNOSoleno Therapeutics-$1.14-$0.95+$0.19-$0.95N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthECORelectroCoreN/AN/AN/AN/AN/AIRIXIRIDEXN/AN/AN/AN/AN/ANDRAENDRA Life SciencesN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioECORelectroCoreN/A1.521.30IRIXIRIDEX4.281.951.27NDRAENDRA Life SciencesN/A3.853.85SLNOSoleno Therapeutics0.2119.6419.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipECORelectroCore26.74%IRIXIRIDEX20.10%NDRAENDRA Life Sciences1.19%SLNOSoleno Therapeutics97.42%Insider OwnershipCompanyInsider OwnershipECORelectroCore19.70%IRIXIRIDEX7.40%NDRAENDRA Life Sciences0.04%SLNOSoleno Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableECORelectroCore507.42 million5.96 millionNot OptionableIRIXIRIDEX12016.79 million15.55 millionOptionableNDRAENDRA Life Sciences20740,000738,000Not OptionableSLNOSoleno Therapeutics3050.39 million47.17 millionOptionableNDRA, SLNO, ECOR, and IRIX HeadlinesRecent News About These CompaniesSoleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells $316,970.80 in Stock5 hours ago | insidertrades.comOppenheimer & Co. Inc. Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)July 4 at 3:19 AM | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Patricia C. Hirano Sells 3,830 SharesJuly 3 at 6:25 PM | marketbeat.comSoleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025July 1 at 8:56 AM | finance.yahoo.comSoleno Therapeutics (NASDAQ:SLNO) Reaches New 1-Year High - What's Next?June 30, 2025 | marketbeat.comLisanti Capital Growth LLC Purchases Shares of 25,365 Soleno Therapeutics, Inc. (NASDAQ:SLNO)June 29, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells $22,410.50 in StockJune 26, 2025 | marketbeat.comSLNO Soleno Therapeutics, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comSoleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome ConferenceJune 25, 2025 | santelog.comSSoleno gains as Betaville cites buyout interest (update)June 24, 2025 | msn.comSoleno Therapeutics (NASDAQ:SLNO) Sets New 1-Year High - Here's What HappenedJune 23, 2025 | marketbeat.comSoleno Therapeutics initiated with a Buy at TD CowenJune 23, 2025 | msn.comFDA Approval for its Drug Lifted Soleno Therapeutics (SLNO) Shares by 60%June 23, 2025 | msn.comSoleno Therapeutics (NASDAQ:SLNO) Coverage Initiated at TD CowenJune 23, 2025 | marketbeat.comSoleno Therapeutics: Overbought On VYKAT Approval EnthusiasmJune 22, 2025 | seekingalpha.comGAMMA Investing LLC Increases Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)June 22, 2025 | marketbeat.comPiper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR ProspectsJune 20, 2025 | msn.comSoleno Therapeutics to Present Research Findings at 2025 International Prader-Willi Syndrome ConferenceJune 20, 2025 | quiverquant.comQSoleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome ConferenceJune 20, 2025 | globenewswire.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Rating of "Buy" from BrokeragesJune 14, 2025 | marketbeat.com434,514 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Acquired by Assenagon Asset Management S.A.June 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeWhiplash for Investors: AeroVironment's Confusing Stock SignalsBy Jeffrey Neal Johnson | July 2, 2025View Whiplash for Investors: AeroVironment's Confusing Stock SignalsNDRA, SLNO, ECOR, and IRIX Company DescriptionselectroCore NASDAQ:ECOR$6.03 +0.67 (+12.50%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$6.04 +0.00 (+0.08%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.IRIDEX NASDAQ:IRIX$0.92 +0.01 (+0.64%) Closing price 07/3/2025 01:29 PM EasternExtended Trading$0.92 0.00 (0.00%) As of 07/3/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.ENDRA Life Sciences NASDAQ:NDRA$3.46 -0.15 (-4.03%) As of 07/3/2025 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.Soleno Therapeutics NASDAQ:SLNO$86.64 +0.43 (+0.49%) Closing price 07/3/2025 02:34 PM EasternExtended Trading$86.64 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case How a Government Loan Changes the Game for Plug Power Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
